Antibe Therapeutics Inc.
ATE
Rankning i aktier
#31785
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aktiekurs
$0.21483059
Senast synkroniserad: 2024-05-07
Marknadsvärde
$11.13M
Förändring (1 dag)
0.34%
Förändring (1 år)
-0.36%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Aktiekurshistorik för Antibe Therapeutics Inc. (ATE)
Högsta slutkurs: $0.22 den 2025-04-01
Lägsta slutkurs: $4.78 den 2014-10-01
Lägsta slutkurs: $4.78 den 2014-10-01
Aktiekurshistorik för Antibe Therapeutics Inc. från 2014 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2025 | -0.02% |
| 2024 | -64.79% |
| 2023 | 73.56% |
| 2022 | -33.35% |
| 2021 | -82.11% |
| 2020 | -6.13% |
| 2019 | 60.42% |
| 2018 | 70.25% |
| 2017 | -45.71% |
| 2016 | 86.85% |
| 2015 | -71.73% |
| 2014 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $101.53 | -20.65% |
US
|
|
| $96.08 | 0.19% |
IE
|
|
| $308.19 | -20.64% |
US
|
|
| $45.59 | -56.10% |
US
|
|
| $47.05 | -17.88% |
DE
|
